Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132145 | 1.00 | BTK (0.55) | BTKCA1CA2CTSKGAA | |
| SCHEMBL10239204 | 1.00 | BTK (0.55) | BTKCA1CA2CTSKGAA | |
| SCHEMBL24874466 | 0.95 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| SCHEMBL13735251 | 0.95 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| SCHEMBL720530 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL8320677 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL720531 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL8220153 | 0.89 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| Ammonia Solution, Strong SCHEMBL28630271 | 0.86 | BTK (0.51) | BTKCA1CA2CTSKGAA | |
| SCHEMBL570801 | 0.83 | GAA (0.54) | BTKCA1CA2CTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600698-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250100998-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025024811-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025011476-A1 | INDAZOLE DERIVATIVE OR PHARMACEUTICAL SALT THEREOF AND USE THEREOF | 浙江大学 | 2025-01-16 | — | — | WO | disclosed |
| CN-119219609-A | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof | 浙江大学 | 2024-12-31 | — | — | CN | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| EP-4277893-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116891460-A | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof | 浙江大学 | 2023-10-17 | — | — | CN | disclosed |
| US-20230174481-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174481-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| EP-4132910-A1 | KINASE INHIBITORS | GB002, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667218-A | Kinase inhibitors | GB005股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3330271-B1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022155111-A1 | INDOLE DERIVATIVES AS KINASE INHIBITORS | GB005, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220009920-A1 | KINASE INHIBITORS | GB005, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009920-A1 | KINASE INHIBITORS | GB005, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600698-B2 | Kinase inhibitors | BTK, BMX, GSK3B | BTK 1/4885CA1 3514/4885CA2 1101/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | BTK 414/4885CA1 2121/4885CA2 1144/4885 |
| US-20250100998-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | BTK 1242/4885CA1 4498/4885CA2 3900/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | BTK 414/4885CA1 2121/4885CA2 1144/4885 |
| US-20230174481-A1 | KINASE INHIBITORS | BTK, LYN, LCK | BTK 1/4885CA1 4600/4885CA2 3888/4885 |
| US-20220009920-A1 | KINASE INHIBITORS | BTK, LYN, LCK | BTK 1/4885CA1 4787/4885CA2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.